⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005762 | 0.82 | RIPK1 (0.30) | — | |
| SCHEMBL178139 | 0.82 | RIPK1 (0.30) | — | |
| SCHEMBL3518081 | 0.80 | — | — | |
| SCHEMBL2067311 | 0.77 | NR1H2 (0.30) | — | |
| SCHEMBL177570 | 0.76 | KIF11 (0.31) | — | |
| SCHEMBL2066894 | 0.73 | — | — | |
| SCHEMBL2068001 | 0.72 | — | — | |
| SCHEMBL8829960 | 0.72 | — | — | |
| SCHEMBL2066693 | 0.72 | NPSR1 (0.30) | — | |
| SCHEMBL1499394 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4359817-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | claimed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | claimed |
| JP-2004537511-A | — | — | 2004-12-16 | — | — | JP | claimed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| EP-1379505-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | disclosed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | disclosed |